Drug intelligence / Profile preview

Interferon alfa-2b vaginal effervescent tablet

Development stage
Unknown
Lead developer
Kawin Technology
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Vaginal
01

Overview

Recombinant Human Interferon alfa-2b Vaginal Effervescent Tablet is a biologic drug developed and marketed by Beijing Kawin Technology. The active ingredient is recombinant human interferon alfa-2b, formulated as a vaginal effervescent tablet containing 0.5 million international units (MIU) per tablet. The drug is a recombinant protein that works by stimulating antiviral immune responses at the mucosal site through interferon-alpha's immunomodulatory mechanisms. It is specifically indicated for the treatment of cervical erosion caused by viral infection and for the prevention and treatment of human papillomavirus (HPV) infection. The product is administered locally by placing one tablet into the vaginal dome, typically once every other day.

Other names
Recombinant Human Interferon alfa-2b Vaginal Effervescent TabletInterferon alfa-2b (vaginal formulation)
02

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)

Beyond the preview

Go deeper on Interferon alfa-2b vaginal effervescent tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interferon alfa-2b vaginal effervescent tablet.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call